## **ONCOLOGY** REFERRAL FORM (A-T)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATIO	N									
Last Name	First Name	DOB	Gen	nder 🗆 M 🛛	🗆 F 🛛 Last	4 SSN		Primary L	anguage	
Address			City				State		ZIP	
Email	Home F	Phone	·	Work Phon	ie			Cell Pr	none	
Primary Contact Method (che	ck one) 🛛 Cell Phone 🛛	Home Phone 🛛 Work Phone	e 🗆 Text	🗆 Email	🗆 Primary	Caregiver		Γ CONTACT		
Primary Caregiver/Alt Contact	Name (If applicable)	Alt Conta	act Email					Alt Conta	ct Phone	
PRESCRIBER INFORMA	TION									
Name of Contact Sending Ref	erral	Title			Preferred (	Contact Met	nod (check	one) 🗆 Ei	mail 🗆 Phone 🛛	Fax
Referral Contact Email		·	Of	ffice Phone			Off	ice Fax		
Practice / Facility Name			Pro	escriber Nan	ne / Specia	lty				
Address			City					State	ZIP	
Prescriber State License #	DEA #		NPI #				Med	icaid UPIN #	ŧ	
	* Please	include a copy of th	e front a	nd back	of insu	rance ca	rd *			
CLINICAL INFORMATIC	DN - Please include ap	plicable clinical chart i	notes							
Patient New to Therapy 🗆 Yes	🛛 No, Start Date of Current	Therapy:				Date	e Medicatio	n Needed		
Treatment History or Failed Th	nerapies (Please also attach r	ecent labs/clinical notes)				I				
Sample/Starter Provided?	No 🗆 Yes, Provide Qty:	Date Provided:	Patien	nt Height (cm	n/in):	Weight	(kg/lbs):	Da	te Obtained:	
Other/Concomitant Medicatio	ns (please list)									
Allergies 🗆 NKDA 🛛 Drug	Allergies (please list)									
Ship to Address 🛛 Home 🛛	□ Prescriber's Office □ Oth	ner (please list)								
ICD-10 Code 🛛 Code:	Description:									
PRESCRIPTION INFORI	MATION - Please Escri	ibe if required by state	law							
In order for a brand name p or your state-specific requi										
			not a valid j	prescriptio	11 10/11/10	writing ct	ond oned i	neuicatioi	15.	
ORAL ONCOLOGY AGENTS	🗆 Braftovi	□ Fareston	🗆 inrel	hic		□ Mercap	topurino		□ Rydapt	
						Mercap     Mesnex	-			
Afinitor Disperz				ali + Femara	Co-Pack	Methot				
				-	CO-Fack					
	Emcyt     Erivedge					□ Nilandr	-			
	Erleada					□ Nilutar	-		□ Sunitinib Malate	
				covorin		□ Nolvad				
									□ Tabrecta	
						Onureg			□ Tafinlar	
	Everolimus Soluble	Imatinib Mesylate	□ Mek			Piqray			□ Talzenna	
			□ Mek				ck		□ Tarceva	
Dose:		Tablets 🗆	Capsules 🗆	Other:			Qty:		Refills:	
Directions:										
BMS REMS PRODUCTS										
REVLIMID <sup>®</sup> 2.5 mg 5	5 mg □ 10 mg □ 15 mg □				Risk	Category				
□ Take 1 capsule PO once daily □ Take 1 capsule PO daily; day		QTY: 28 QTY: 21	-	) Refills ) Refills		ULT Female, ULT Female,		•		
□ Other:		QTY:		) Refills	DAD	ULT Male nale CHILD,	•			
THALOMID <sup>∗</sup> □ 50 mg □ 1	100 mg 🛛 150 mg 🗌 200 r	ng			🗆 Fer	nale CHILD,				
□ Take 1 capsule PO once daily	у.	QTY: 28		) Refills ) Refills		le CHILD				
		QTY:	0	Renns	-	Issued:				
_	mg □3 mg □4 mg									
Take 1 capsule PO once daily     Other:	y, days 1-21 of 28-day cycle.	QTY: 21 QTY:		) Refills ) Refills	Date	Issued:				
					I					
Prescriber Signature		Date	Supe	rvising Physi	cian Signat	ure (where	required bv	state law)	Date	
-										
DAW (Dispense as Written)		Date	Brand	d Necessary	(must hanc	lwrite)				
<b>Note:</b> The information contained in this language, number of prescriptions allow										
Confidentiality Statement: This messag										

Contraentiality Statement: Inis message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

REV.12.18.23

## **ONCOLOGY** REFERRAL FORM (T-Z)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

	l									
Last Name	First Nam	e D	ОВ		Gender 🗆 M	□F	Last 4 SSN		Primary La	nguage
Address				City				State		ZIP
Email		Home Phone			Work Pho	one			Cell Pho	one
Primary Contact Method (cheo	k one) 🗆 Cell Pho	one 🛛 Home Phone	U Work Phone	e 🗆 Tex	kt 🗆 Email	🗆 Pri	mary Caregiver		T CONTACT	
Primary Caregiver/Alt Contact	Name (If applicable	;)	Alt Conta	ct Email					Alt Contact	t Phone
PRESCRIBER INFORMA	TION									
Name of Contact Sending Refe	rral		Title			Prefe	erred Contact Me	hod (check	one) 🗆 Em	ail 🗆 Phone 🗆 Fax
Referral Contact Email					Office Phone			Of	fice Fax	
Practice / Facility Name					Prescriber Na	me / s	Specialty			
Address				Ci	ty				State	ZIP
Prescriber State License #	DE	EA #		NF	PI #			Mec	licaid UPIN #	
		Please include a			t and back	k of I	insurance ca	ard *		
CLINICAL INFORMATIO			inical chart n	notes			1			
Patient New to Therapy  Ves							Da	te Medicatio	on Needed	
Treatment History or Failed The				1						
Sample/Starter Provided?		ty: Date Prov	Ided:	Pa	tient Height (c	m/in):	Weight	(kg/lbs):	Date	e Obtained:
Other/Concomitant Medication										
	Allergies (please list									
	Prescriber's Office		)							
ICD-10 Code 🗆 Code:	Description:									
PRESCRIPTION INFORM In order for a brand name p					rand Necessa	rv" or	· "Brand Medica	allv Necess	sarv."	
or your state-specific requir										5.
ORAL ONCOLOGY AGENTS										
Targretin	🗆 Xtandi	□ Other:								
🗆 Tasigna	🗆 Xatmep	□ Other:								
🗆 Temodar	🗆 Yonsa	□ Other:								
Temozolomide	🗆 Zolinza	🗆 Other:								
Toremifene Citrate	🗆 Zykadia	🗆 Other:								
Tretinoin	🗆 Zytiga	🗆 Other:								
🗆 Tykerb	□ Other:									
Vizimpro	□ Other:									
Votrient	-									
	□ Other:									
🗆 Xalkori	☐ Other: □ Other:									
□ Xalkori □ Xeloda										
	□ Other:		Tablets 🗆 (	Capsules	Other:			Qty:		Refills:
🗆 Xeloda	□ Other:		□ Tablets □ 0	Capsules	Other:			Qty: _		Refills:
Xeloda	□ Other:		Tablets 0	Capsules	□ Other:			Qty: _		Refills:
C Xeloda  Dose: Directions: BMS REMS PRODUCTS	Other: Other:	5 mg 🗆 20 mg 🗆 25		Capsules	Other:		Risk Category	Qty: _		Refills:
	Other:     Other:		i mg QTY: 28 QTY: 21	 	0 Refills 0 Refills		Risk Category	e, NOT of Ro	eproductive P	otential
Xeloda      Dose: Directions:  BMS REMS PRODUCTS      REVLIMID*	Other:     Other:	e	i mg QTY: 28	 	0 Refills		Risk Category ADULT Female ADULT Female ADULT Male Female CHILD	e, NOT of Re e, Reproduc , NOT of Re	eproductive P tive Potential productive Po	votential
Xeloda      Dose: Directions: BMS REMS PRODUCTS      REVLIMID* 2.5 mg 5      Take 1 capsule PO once daily;     Take 1 capsule PO daily; days     Other: THALOMID* 50 mg 11      Take 1 capsule PO once daily;	Other: Other: Other: mg 10 mg 1	e	i mg QTY: 28 QTY: 21 QTY: QTY: 28		O Refills O Refills O Refills O Refills		Risk Category ADULT Female ADULT Female ADULT Female Female CHILD Male CHILD	e, NOT of Ro a, Reproduc , NOT of Re , Reproduct	eproductive P tive Potential productive Potential	otential
Xeloda      Dose: Directions: BMS REMS PRODUCTS      REVLIMID*	Other: Other: Other: mg 10 mg 1	e.  200 mg 	i mg QTY: 28 QTY: 21 QTY:		O Refills O Refills O Refills		Risk Category ADULT Female ADULT Female DULT Female CHILD Female CHILD Female CHILD	e, NOT of R e, Reproduc , NOT of Re , Reproduct	eproductive P tive Potential productive Potential ive Potential	otential
Xeloda         Dose:         Directions:         BMS REMS PRODUCTS         REVLIMID*       2.5 mg         Take 1 capsule PO once daily;         Take 1 capsule PO daily; days         Other:         THALOMID*       50 mg         Take 1 capsule PO once daily;         Other:         POMALYST*       1 mg	□ Other: □ Other: mg □ 10 mg □ 1	e. 2200 mg 	i mg QTY: 28 QTY: 21 QTY: QTY: QTY:		O Refills O Refills O Refills O Refills O Refills		Risk Category ADULT Female ADULT Female ADULT Male Female CHILD Female CHILD Male CHILD Celgene Auth #:	e, NOT of Re , Reproduc , NOT of Re , Reproduct	eproductive P tive Potential productive Potential ive Potential	otential
Xeloda      Dose: Directions: BMS REMS PRODUCTS      REVLIMID*	□ Other: □ Other: mg □ 10 mg □ 1	e. 2200 mg 	i mg QTY: 28 QTY: 21 QTY: QTY: 28	- -	O Refills O Refills O Refills O Refills		Risk Category ADULT Female ADULT Female Female CHILD Female CHILD Male CHILD Celgene Auth #: Date Issued:	e, NOT of Re e, Reproduc , NOT of Re , Reproduct	eproductive P tive Potential productive P ive Potential	otential
Xeloda         Dose:         Directions:         BMS REMS PRODUCTS         REVLIMID*       2.5 mg         Take 1 capsule PO once daily;         Other:         THALOMID*       50 mg         Take 1 capsule PO once daily;         Other:         THALOMID*       50 mg         Take 1 capsule PO once daily;         Other:         Take 1 capsule PO once daily;         Take 1 capsule PO once daily;         Take 1 capsule PO once daily;         Other:         POMALYST*       1 mg         Take 1 capsule PO once daily;	□ Other: □ Other: mg □ 10 mg □ 1	e. 2200 mg 	i mg QTY: 28 QTY: 21 QTY: QTY: 28 QTY: QTY: 21		O Refills O Refills O Refills O Refills O Refills O Refills O Refills		Risk Category ADULT Female ADULT Female ADULT Male Female CHILD Male CHILD Celgene Auth #: Date Issued: Confirmation #:	e, NOT of Re e, Reproduct , NOT of Re , Reproduct	eproductive P tive Potential productive Pu ive Potential	otential
Xeloda  Dose: Directions: BMS REMS PRODUCTS  REVLIMID*	□ Other: □ Other: mg □ 10 mg □ 1	e.  200 mg  ng y cycle. 	i mg QTY: 28 QTY: 21 QTY: QTY: 28 QTY: QTY: 21	- - - - - - -	O Refills O Refills O Refills O Refills O Refills O Refills O Refills	sician	Risk Category ADULT Female ADULT Female ADULT Female Female CHILD Female CHILD Gelgene Auth #: Date Issued: Confirmation #: Date Issued: Signature (where	e, NOT of Re e, Reproduct , NOT of Re , Reproduct	eproductive P tive Potential productive Pu ive Potential	'otential           otential

Contrachtaity Statement: Inis message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and contralential. It may also contain privileged, contralential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.